Targeted Therapeutics that Address Unmet Medical Needs

Inflammatory Bowel Disease (IBD) is complex and heterogeneous. A ‘one-size-fits-all’ standardized treatment may not be effective for many patients. In fact, 75% of the 2 million patients in the US who have IBD are refractory to first line biologic therapy¹.

Prometheus Biosciences is pioneering a precision medicine approach for the treatment of IBD. We merge access to hundreds of thousands of patient samples with advances in machine learning and data mining tools to understand the link between patients’ symptoms and disease-driving biomarkers. We use these breakthroughs to identify novel therapeutic targets and diagnostic tests to address the unmet medical needs. 

Therapeutic Pipeline

Program
IBD Population
Target Validation
Pre-Clinical Studies
Phase 1
PR200 - anti-TL1A mAb.
UC/CD
PR300 - small molecule
UC
PR600 - mAb
UC/CD
TPR10 - small molecule
UC
Partnered
TPR15 - mAb
CD
Partnered
TPR20 - mAb
UC/CD
Partnered

UC: Ulcerative Colitis      CD: Crohn’s Disease

PR200UC/CD Pre-Clinical Studies
PR300UC Pre-Clinical Studies
PR600UC/CD Target Validation
TPR10UC Pre-Clinical Studies
TPR15CD Pre-Clinical Studies
TPR20UC/CD Target Validation

Core Research Principles

The target is a true driver of disease in a defined IBD sub-phenotype

We can develop a selective medicine that has best-in-class potential

We can identify pathway-specific enrichment biomarkers

We can pre-identify and enroll the appropriate patients

Allowing us to deliver drugs with

  • superior label claims, first-line use
  • an accelerated, efficient path to the clinical and market

Reference:
1. Singh S. Fumery M, Sandborn WJ, Murad MH. Systemic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn’s disease. Aliment Pharmacol Ther. 2018 ;48:394–409